Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Cedars-Sinai Medical Center | OTHER |
Not provided
Not provided
Not provided
Not provided
This is a small, exploratory study that will investigate using an artificial intelligence (AI) and virtual reality (VR), digital wellness application (app) to deliver a mental health support session in outpatient and hospitalized patients with inflammatory bowel disease (IBD) and co-existing symptoms of mild to moderate anxiety or depression.
The purpose of this study is to explore if a mental health support session using the app is feasible, safe, and acceptable to IBD patients and whether it could possibly help with physical and comorbid psychological symptoms of these patients.
The mental health support session is delivered by a virtual reality digital wellness application (app). The app is a Chat GPT-4 powered AI and VR platform called XAIA (eXtended reality Artificially Intelligent Ally). [Chat GPT is an AI program that generates dialogue.] The app is publicly available on the Apple Vision Pro (a VR tool). It was developed by a group of providers, including a psychiatrist, at Cedars-Sinai Medical Center to devise a scalable solution for the increasing demand for mental wellness experiences. The application uses the combination of an AI-powered virtual avatar, named "XAIA," and a VR environment to deliver immersive and personalized mental health support in mixed-reality environments.
This is a mixed method study with primarily a qualitative focus. Patients with IBD who self-report mild to moderate levels of anxiety or depression will be invited to try a single AI-VR mental health support session using the XAIA app. Participant observations, experiences, and opinions of the application will be collected through surveys and semi-structured interviews. Pre- and post- session pain and state anxiety scores will be collected.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with IBD who self-report mild to moderate levels of anxiety or depression | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Mental health support session | Behavioral | a single AI-VR mental health support session using the XAIA application |
|
| Measure | Description | Time Frame |
|---|---|---|
| Determine the feasibility of utilizing a GPT-4-powered AI-VR mental health support session in patients with IBD | Measured via a post-session, semi-structured interview | Day 1 post-session |
| Determine the safety of utilizing a GPT-4-powered AI-VR mental health support session in patients with IBD | Measured by proportion of subjects with at least one adverse event | Day 1 post-session |
| Determine the patient acceptance of utilizing a GPT-4-powered AI-VR mental health support session in patients with IBD | Measured via Session Rating Scale (SRS V.3.0), which is a visual analogue scale that measures self-reported effective therapeutic relationships. Scores range from 0 to 40, with higher scores indicating more effective relationships. Scores are commonly classified as "any score lower than 36 overall, or 9 on any [of the 4] scale[s], could be a source of concern..." | Day 1 post-session |
| Measure | Description | Time Frame |
|---|---|---|
| To assess change in pain scores pre- and post-session | Measured via Visual Analogue Pain Scale, which is a scale that measures self-reported pain intensity. Scores range from 0-10, with higher scores indicating greater pain intensity. Scores are commonly classified as "no pain" (0), "mild pain" (1-3), "moderate to severe pain" (4-6), "very severe pain" (7-9), "worst possible pain" (10). | Day 1 pre-session; Day 1 post-session |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David T Rubin, MD | University of Chicago | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Chicago | Chicago | Illinois | 60637 | United States |
Not provided
| ID | Term |
|---|---|
| D015212 | Inflammatory Bowel Diseases |
| D001008 | Anxiety Disorders |
| D003863 | Depression |
| D003093 | Colitis, Ulcerative |
| D003424 | Crohn Disease |
| ID | Term |
|---|---|
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D007410 | Intestinal Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| To assess change in mood scores pre- and post-session | Spielberger State-Trait Anxiety Inventory (STAI), which is a tool that measures self-reported anxiety. Scores range from 0-40, with higher scores indicating greater anxiety. STAI scores are commonly classified as "no or low anxiety" (20-37), "moderate anxiety" (38-44), and "high anxiety" (45-80). | Day 1 pre-session; Day 1 post-session |
| To characterize any limitations for creating a AI-VR mental health support tool optimally aligned with the needs of patients with IBD | Measured via a post-session, semi-structured interview | Day 1 post-session |
| To characterize any potential future improvements for creating a AI-VR mental health support tool optimally aligned with the needs of patients with IBD | Measured via a post-session, semi-structured interview | Day 1 post-session |
| D001523 | Mental Disorders |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
| D003092 | Colitis |
| D003108 | Colonic Diseases |